BenevolentAI Bio   Report issue

For profit Phase 2
Founded: London United Kingdom (2013)

Organization Overview

First Clinical Trial
2017
NCT03194217
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

BenevolentAI Bio

Active Ingredients

Drugs in Phase 2 Trials (2)

bavisant (1 trial)

ben2293 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 2)

Sleepiness (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2